Search company, investor...
ReaMetrix company logo


Founded Year



Unattributed VC | Alive

Total Raised




Last Raised

$2.1M | 13 yrs ago

About ReaMetrix

ReaMetrix, Inc. is a US and India-based biotechnology company aiming to provide high quality research and diagnostic assay solutions resulting in a transformation of the cost opportunities available in India into value for both the biotechnology and global health sectors. ReaMetrix's belief is that Indian resources will bring significant value to identifying and addressing the health care needs of the developing world, and that the resulting products will often translate into more affordable alternatives in the developed world.

Headquarters Location

1585 Industrial Road

San Carlos, California, 94070,

United States


Missing: ReaMetrix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ReaMetrix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

ReaMetrix Patents

ReaMetrix has filed 20 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Diffraction
  • Fluid dynamics
patents chart

Application Date

Grant Date


Related Topics




Gliders, Biotechnology, Molecular biology, Fluid dynamics, Microbiology


Application Date


Grant Date



Related Topics

Gliders, Biotechnology, Molecular biology, Fluid dynamics, Microbiology



ReaMetrix Frequently Asked Questions (FAQ)

  • When was ReaMetrix founded?

    ReaMetrix was founded in 2003.

  • Where is ReaMetrix's headquarters?

    ReaMetrix's headquarters is located at 1585 Industrial Road, San Carlos.

  • What is ReaMetrix's latest funding round?

    ReaMetrix's latest funding round is Unattributed VC.

  • How much did ReaMetrix raise?

    ReaMetrix raised a total of $5.65M.

  • Who are the investors of ReaMetrix?

    Investors of ReaMetrix include Mobius Venture Capital, Sequoia Capital India, Baring Private Equity Partners and Sequoia Capital.

  • Who are ReaMetrix's competitors?

    Competitors of ReaMetrix include BioDot, ZyGEM, CareDx, Evogen, Life Technologies Corporation and 12 more.

Compare ReaMetrix to Competitors

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Immunetrics Logo

Nobody prototypes a jet plane or car without running the empirical data through a computer model. A clinical trial is also a prototype. Now, pharmaceutical companies can simulate as many scenarios as necessary to optimize success in the final design of their clinical trials.nBiosimulation technology from Immunetrics Inc. aims to provide a bridge from research and experiment to trial design. Immunetrics' toolset aims to provide predictive computer models based on biological mechanisms. The inputs are patient data; the outputs are predictions of clinical markers over time and clinically relevant endpoints. Using this data, Immunetrics creates a simulation platform for conducting virtual experiments that can help pharmaceutical companies lock down the design of a human study that is optimized for success.nImmunetrics is the only known mechanistic modeling company to provide predictions of clinical trial outcomes that go far beyond pass or fail.

Axela Biosensors

Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.


EMTech, a spin-off of BiOva, LLC, is researching, developing, and manufacturing technologies for the metabolic enhancement of the enzymes and bacteria used in the fermentation industry. The company's current products and ongoing research projects show applications that enhance productivity in the ethanol, pharmaceutical, beer, wine, and dairy industries.

American Biosystems

American Biosystems, Inc., produces and markets biological products used in Agriculture, Aquaculture and Industry. Specialized bacterial cultures are grown and harvested to produce enzymes ... nature's catalysts. These products can be incorporated into animal feed as a natural alternative to hormones and antibiotics while providing many of the same benefits. For Aquaculture, bacteria digest uneaten feed and waste products, providing cleaner water and producing less stress on farm-raised shrimp. For Industry, target markets include complex manufacturing processes, bio-medical cleaning products, waste reduction and recycling. Bacteria and the enzymes they produce are nature's way of breaking down wastes into harmless components or building blocks man can use to rebuild or remake other products. The company was founded in 1982 by Lewis E. Goyette, Ph.D, and is now managed by his son Edward M. Goyette. The company markets in over 15 countries through overseas distributors and currently has two employees in The New Century Venture Center. American Biosystems moved into the center on May 31, 2002.


Invivo Sciences technology aims to bridge the gap in preclinical research performed using animal models and cell culture systems. Per the company, the advances in lab-automation coupled with the company's expertise in tissue engineering allows InvivoSciences to commercialize fast, reliable, and cost effective screening systems.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.